Cure51

Cure51 is a TechBio company building the world's first large-scale database of long-term cancer survivors — patients who have survived more than five years after diagnosis of typically lethal cancers. Co-founded with leading global oncology centers including Institut Gustave Roussy and MD Anderson, the company has enrolled over 1,500 survivors across 42 countries and conducts multi-omic sequencing to identify robust therapeutic targets. Its computational biology and machine learning teams translate survivor biology into novel drug development candidates and precision medicine tools, with an initial focus on three aggressive cancer types.